{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:13:57Z","timestamp":1787973237650,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T00:00:00Z","timestamp":1741478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05544-1","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T04:30:17Z","timestamp":1741494617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of disitamab vedotin in combination with immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Ji-Ming","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,9]]},"reference":[{"key":"5544_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, et al. 2024 Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin","DOI":"10.3322\/caac.21834"},{"issue":"6","key":"5544_CR2","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/bju.12468","volume":"113","author":"GB Boustead","year":"2014","unstructured":"Boustead GB et al (2014) Stage, grade and pathological characteristics of bladder cancer in the UK: British association of urological surgeons (BAUS) urological tumour registry. BJU Int 113(6):924\u2013930","journal-title":"BJU Int"},{"issue":"1","key":"5544_CR3","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"5544_CR4","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z et al (2024) Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: a combined analysis of two phase II clinical trials. J Clin Oncol 42(12):1391\u20131402","journal-title":"J Clin Oncol"},{"issue":"1","key":"5544_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"WJ Alfred","year":"2024","unstructured":"Alfred WJ et al (2024) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85(1):17\u201331","journal-title":"Eur Urol"},{"issue":"5","key":"5544_CR6","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD (2020) Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 70(5):404\u2013423","journal-title":"CA Cancer J Clin"},{"issue":"13","key":"5544_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T et al (2020) Avelumab maintenance therapy for advanced or mUC. N Engl J Med 383(13):1218\u20131230","journal-title":"N Engl J Med"},{"issue":"6","key":"5544_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.21037\/apm-22-1350","volume":"12","author":"M Uccello","year":"2023","unstructured":"Uccello M et al (2023) Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence. Ann Palliat Med 12(6):1345\u20131354","journal-title":"Ann Palliat Med"},{"key":"5544_CR9","volume":"10","author":"M Qu","year":"2023","unstructured":"Qu M et al (2023) Advances in HER2-targeted treatment for advanced\/mUC. Bladder (San Franc) 10:e21200012","journal-title":"Bladder (San Franc)"},{"issue":"1","key":"5544_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F et al (2022) Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy. Drug Deliv 29(1):1335\u20131344","journal-title":"Drug Deliv"},{"issue":"2","key":"5544_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M et al (2012) Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30(2):191\u2013199","journal-title":"J Clin Oncol"},{"issue":"19","key":"5544_CR12","first-page":"JCO2201792","volume":"41","author":"P Thomas","year":"2023","unstructured":"Thomas P, Hoon SP, Claudia C et al (2023) Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN bladder 100 trial after \u22652 years of follow-up. J Clin Oncol: Off J Am Soc Clin Oncol 41(19):JCO2201792\u2013JCO2201792","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"12","key":"5544_CR13","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles T et al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 384(12):1125\u20131135","journal-title":"N Engl J Med"},{"key":"5544_CR14","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","volume":"30","author":"WF Maguire","year":"2024","unstructured":"Maguire WF et al (2024) FDA approval summary: enfortumab vedotin plus pembrolizumab for cisplatin-ineligible locally advanced or mUC. Clin Cancer Res 30:2011\u20132016","journal-title":"Clin Cancer Res"},{"issue":"22","key":"5544_CR15","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST et al (2021) TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with mUC progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 39(22):2474\u20132485","journal-title":"J Clin Oncol"},{"issue":"4","key":"5544_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/14737140.2022.2049763","volume":"22","author":"TV Mathew","year":"2022","unstructured":"Mathew TV et al (2022) Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther 22(4):335\u2013341","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"5544_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X et al (2021) Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 27(1):43\u201351","journal-title":"Clin Cancer Res"},{"key":"5544_CR18","first-page":"JCO2202912","volume":"42","author":"X Sheng","year":"2023","unstructured":"Sheng X et al (2023) Efficacy and Safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or mUC: a combined analysis of two phase II clinical trials. J Clin Oncol 42:JCO2202912","journal-title":"J Clin Oncol"},{"key":"5544_CR19","doi-asserted-by":"crossref","unstructured":"Xu H, Sheng X, Zhou L, et al. 2022 A phase II study of RC48-ADC in HER2-negative patients with locally advanced or mUC. J Clin Oncol, 40, (suppl 16; abstr 4519)","DOI":"10.1200\/JCO.2022.40.16_suppl.4519"},{"key":"5544_CR20","doi-asserted-by":"crossref","unstructured":"Sheng X, Zhou L, He Z, et al. 2022 Preliminary results of a phase Ib\/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4mAb against programmed death-1 (PD-1) in patients with locally advanced or mUC. J Clin Oncol 40, (suppl 16; abstr 4518)","DOI":"10.1200\/JCO.2022.40.16_suppl.4518"},{"issue":"8","key":"5544_CR21","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"Z Li","year":"2023","unstructured":"Li Z, Zhiting S, Yiqiang L et al (2023) HER2 expression associated with clinical characteristics and prognosis of urothelial carcinoma in a chinese population. Oncologist 28(8):e617\u2013e624","journal-title":"Oncologist"},{"issue":"23","key":"5544_CR22","doi-asserted-by":"publisher","first-page":"21159","DOI":"10.1002\/cam4.6680","volume":"12","author":"J Xu","year":"2023","unstructured":"Xu J, Zhang H, Zhang L et al (2023) Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: a multicenter, retrospective clinical study. Cancer Med 12(23):21159\u201321171","journal-title":"Cancer Med"},{"issue":"1","key":"5544_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","volume":"153","author":"X Yao","year":"2015","unstructured":"Yao X, Jiang J, Wang X et al (2015) A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res Treat 153(1):123\u2013133","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"5544_CR24","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A et al (2012) Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12(12):860\u2013875","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"5544_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","volume":"36","author":"L Zhou","year":"2024","unstructured":"Zhou L, Yang WK, Zhang S et al (2024) Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase 1b\/2 dose-escalation and dose-expansion study. Ann Oncol: Off J Euro Soc Med Oncol 36(3):331\u2013339","journal-title":"Ann Oncol: Off J Euro Soc Med Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05544-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05544-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:31Z","timestamp":1767996211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05544-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,9]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5544"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05544-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,9]]},"assertion":[{"value":"25 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical data were retrieved with approval of the institutional review board of the First Affiliated Hospital of Nanchang University, and the Second Affiliated Hospital of Nanchang University. Informed consent was not required for this report because it is a retrospective study. Data analysis of clinical records has no relevance to human biological ethic problems. The study protocol was also approved by the institutional review board of the First Affiliated Hospital of Nanchang University, and the analyses were in accordance with the principles of the Declaration of Helsinki. All methods were performed under relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"154"}}